Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$4.03 +10.6%	$3.82	$2.60 ▼ $7.77	$229.07M	1.56	177,488 shs	53,858 shs
FDMT 4D Molecular Therapeutics	$4.45 +5.5%	$3.81	$2.24 ▼ $28.93	$206.17M	2.81	812,461 shs	153,666 shs
NBTX Nanobiotix	$5.45 +0.3%	$4.25	$2.76 ▼ $6.00	$256.81M	0.41	15,422 shs	731 shs
OSTX OS Therapies	$1.70 +4.9%	$1.78	$1.12 ▼ $7.00	$47.74M	N/A	491,479 shs	263,365 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	+2.82%	+3.41%	-9.23%	+22.97%	+4.00%
FDMT 4D Molecular Therapeutics	+6.84%	+1.69%	-2.99%	+52.90%	-80.36%
NBTX Nanobiotix	+14.41%	+12.54%	+15.29%	+66.31%	+2.45%
OSTX OS Therapies	-6.36%	-16.06%	-2.99%	+20.90%	+161,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DSGN Design Therapeutics	0.378 of 5 stars	1.0	1.0	0.6	2.5	0.6
FDMT 4D Molecular Therapeutics	2.2835 of 5 stars	3.3	2.0	2.3	1.7	0.6
NBTX Nanobiotix	1.6891 of 5 stars	3.3	3.0	1.1	0.0	0.6
OSTX OS Therapies	2.7842 of 5 stars	3.7	0.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSGN Design Therapeutics	2.00	Hold	$4.00	-0.65% Downside
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	564.17% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	46.82% Upside
OSTX OS Therapies	3.40	Buy	$18.00	958.82% Upside

Current Analyst Ratings Breakdown

Latest OSTX, DSGN, FDMT, and NBTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/27/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/15/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/10/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/9/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00
5/9/2025	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00

(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$4.28 per share	N/A
FDMT 4D Molecular Therapeutics	$40K	5,154.21	N/A	N/A	$11.05 per share	0.40
NBTX Nanobiotix	$39.18M	6.55	N/A	N/A	($1.51) per share	-3.61
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSGN Design Therapeutics	-$49.59M	-$0.99	N/A	N/A	N/A	N/A	-22.85%	-22.02%	8/4/2025 (Estimated)
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/6/2025 (Estimated)
NBTX Nanobiotix	-$73.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/16/2025 (Estimated)
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A

Latest OSTX, DSGN, FDMT, and NBTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	FDMT 4D Molecular Therapeutics	-$0.6922	N/A	N/A	N/A	$0.52 million	N/A
8/4/2025	Q1 2025	DSGN Design Therapeutics	-$0.32	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	DSGN Design Therapeutics	-$0.28	-$0.31	-$0.03	-$0.31	N/A	N/A
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSGN Design Therapeutics	N/A	28.37	28.37
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
NBTX Nanobiotix	N/A	1.04	1.04
OSTX OS Therapies	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSGN Design Therapeutics	56.64%
FDMT 4D Molecular Therapeutics	99.27%
NBTX Nanobiotix	38.81%
OSTX OS Therapies	N/A

Insider Ownership

Company	Insider Ownership
DSGN Design Therapeutics	31.20%
FDMT 4D Molecular Therapeutics	9.60%
NBTX Nanobiotix	3.45%
OSTX OS Therapies	13.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSGN Design Therapeutics	40	56.77 million	39.06 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
NBTX Nanobiotix	100	47.13 million	45.51 million	Not Optionable
OSTX OS Therapies	N/A	28.10 million	N/A	N/A

OSTX, DSGN, FDMT, and NBTX Headlines

Recent News About These Companies

Analysts Conflicted on These Healthcare Names: OS Therapies Incorporated (OSTX), Korro Bio (KRRO) and Veeva Systems (VEEV)

July 3, 2025 | theglobeandmail.com

OSTX - OS Therapies Inc Executives - Morningstar

July 3, 2025 | morningstar.comM

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

July 3, 2025 | businesswire.com

Positive Buy Rating for OS Therapies Driven by Promising Phase 2b Trial Results and Regulatory Progress

July 2, 2025 | tipranks.com

OS Therapies' (OSTX) Buy Rating Reaffirmed at D. Boral Capital

July 1, 2025 | americanbankingnews.com

OS Therapies' (OSTX) "Buy" Rating Reaffirmed at D. Boral Capital

June 30, 2025 | marketbeat.com

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor ...

June 30, 2025 | finance.yahoo.com

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference

June 30, 2025 | businesswire.com

OS Therapies Stock Surges 12.4% After Positive FDA Feedback on OST-HER2

June 24, 2025 | msn.com

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

June 24, 2025 | businesswire.com

OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

June 23, 2025 | businesswire.com

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

June 10, 2025 | prnewswire.com

OSTX OS Therapies Incorporated

June 1, 2025 | seekingalpha.com

Buy Rating for OS Therapies: Promising Developments and Strategic Positioning in Cancer Immunotherapy

May 21, 2025 | tipranks.com

OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | businesswire.com

OS Therapies Launches Subsidiary To Commercialize Canine Osteosarcoma Treatment

May 16, 2025 | finanzen.atF

OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma

May 15, 2025 | finance.yahoo.com

OS Therapies Inc (NYSE:OSTX) Major Shareholder Shalom Auerbach Sells 82,000 Shares

May 10, 2025 | insidertrades.com

OS Therapies Inc sees $163,918 in stock sales by major shareholder

May 9, 2025 | investing.com

OS Therapies secures patent for cancer immunotherapy tech

May 8, 2025 | investing.com

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

May 2, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSTX, DSGN, FDMT, and NBTX Company Descriptions

Design Therapeutics NASDAQ:DSGN

$4.03 +0.39 (+10.60%)

As of 12:45 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

4D Molecular Therapeutics NASDAQ:FDMT

$4.45 +0.23 (+5.45%)

As of 12:46 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Nanobiotix NASDAQ:NBTX

$5.45 +0.02 (+0.35%)

As of 12:36 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

OS Therapies NYSE:OSTX

$1.70 +0.08 (+4.94%)

As of 12:45 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time